GGHC
TXMD icon

Gilder Gagnon Howe & Co’s TherapeuticsMD TXMD Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,939
Closed -$1.49M – 305
2017
Q4 		$1.49M Sell
4,939
-44,476
-90% -$12.4M 0.02% 205
2017
Q3 		$13.1M Sell
49,415
-11,259
-19% -$3.26M 0.18% 99
2017
Q2 		$16M Sell
60,674
-520
-0.8% -$130K 0.24% 92
2017
Q1 		$22M Sell
61,194
-7,029
-10% -$2.18M 0.37% 73
2016
Q4 		$19.7M Sell
68,223
-4,504
-6% -$1.4M 0.39% 70
2016
Q3 		$24.8M Sell
72,727
-26,494
-27% -$9.68M 0.43% 62
2016
Q2 		$42.2M Sell
99,221
-1,693
-2% -$698K 0.84% 40
2016
Q1 		$32.3M Sell
100,914
-1,083
-1% -$369K 0.63% 44
2015
Q4 		$52.9M Sell
101,997
-1,254
-1% -$463K 0.85% 29
2015
Q3 		$30.3M Sell
103,251
-416
-0.4% -$148K 0.48% 59
2015
Q2 		$40.7M Sell
103,667
-18,142
-15% -$6.4M 0.54% 52
2015
Q1 		$36.8M Buy
121,809
+1,908
+2% +$466K 0.51% 50
2014
Q4 		$26.7M Sell
119,901
-2,027
-2% -$418K 0.4% 64
2014
Q3 		$28.3M Sell
121,928
-799
-0.7% -$201K 0.41% 59
2014
Q2 		$27.1M Sell
122,727
-435
-0.4% -$96.8K 0.36% 63
2014
Q1 		$38.9M Sell
123,162
-27,791
-18% -$8.85M 0.53% 60
2013
Q4 		$39.3M Buy
150,953
+85,481
+131% +$18.7M 0.56% 55
2013
Q3 		$9.59M Buy
65,472
+55,180
+536% +$6.67M 0.15% 106
2013
Q2 		$1.56M Buy
+10,292
New +$1.41M 0.03% 203

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Gilder Gagnon Howe & Co's TXMD Position: Q1 2018 in Review

Gilder Gagnon Howe & Co sold out of TherapeuticsMD (TXMD) in Q1 2018, closing a stake of 4,939 shares — an estimated $1.49M sold.

Gilder Gagnon Howe & Co first reported a position in TXMD in Q2 2013 and held it in 19 quarters. The position peaked at $52.9M in Q4 2015. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2018.

  • Gilder Gagnon Howe & Co reported no remaining TherapeuticsMD position as of Q1 2018 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 4,939 TherapeuticsMD shares in Q1 2018, an estimated $1.49M.
  • Gilder Gagnon Howe & Co first reported a position in TherapeuticsMD in Q2 2013 and held it in 19 quarters.
  • Gilder Gagnon Howe & Co's TherapeuticsMD position peaked at $52.9M in Q4 2015.
  • 143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2018.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2018, filed 30 Apr 2018.